BillionToOne Welcomes Anthony Pagano as New Audit Committee Chair and Board Member

BillionToOne Strengthens Leadership with New Appointment

BillionToOne, Inc., a prominent player in the molecular diagnostics sector, has announced the significant appointment of Anthony Pagano to its Board of Directors as the Chair of the Audit Committee. The decision becomes effective on January 1, 2026. With a vision to enhance the accuracy and accessibility of diagnostic tests, BillionToOne continues its journey towards innovation through strategic leadership additions.

Anthony Pagano's impressive background includes his current role as Chief Financial Officer and Executive Vice President of Genmab, an internationally recognized biotechnology firm. Since joining Genmab in 2007, Pagano has propelled the company's financial growth dramatically, showcasing an extraordinary ability to navigate complex financial landscapes. Under his leadership, Genmab has evolved from generating $100 million to over $3 billion in annual revenues, illustrating his significant impact on developing and commercializing innovative therapeutic solutions.

Prior to his tenure at Genmab, Pagano gained valuable experience at NovaDel Pharma, where he served as Corporate Controller and Senior Director. His career trajectory started at KPMG LLP, where he refined his skills in audit and business strategy across a variety of industries, enabling him to develop a diverse understanding of financial challenges and opportunities.

In comments regarding his appointment, Pagano expressed enthusiasm about contributing to BillionToOne’s mission, stating, "I am honored to support this important mission. Having witnessed the power of innovation in life sciences throughout my career, I am impressed by BillionToOne's technology and team. I look forward to working with the Board and management as the company enters its next phase of growth." His confidence in the company’s potential aligns with BillionToOne’s commitment to transforming the diagnostics space through cutting-edge solutions.

Dr. Oguzhan Atay, the co-founder and CEO of BillionToOne, echoed these sentiments, emphasizing that Pagano's experience would greatly enhance the Board's capabilities. “Anthony's appointment significantly strengthens our Board. I believe his deep financial acumen and proven leadership in guiding high-growth life sciences companies will be instrumental in our mission to create a category-defining, transformative molecular diagnostics company.”

BillionToOne is recognized for its pioneering work in molecular diagnostics, with a focus on developing powerful and precise testing methodologies. The company’s patented Quantitative Counting Templates™ (QCT™) technology revolutionizes how DNA molecules are quantified, establishing a standard for accuracy in the field.

As the company looks to the future, Pagano’s extensive financial background and success in the biotech industry position him to provide crucial insights as BillionToOne continues to advance its innovative technologies. The company is positioned to make a substantial impact on the diagnostics landscape, emphasizing the accessibility and usefulness of its groundbreaking tests.

In addition to Bolstering its leadership team with Pagano, BillionToOne remains committed to its foundational mission: ensuring that powerful and accurate diagnostic tests can benefit everyone. This commitment is reflected in its ongoing research and development efforts, aimed at expanding both the variety and precision of its offerings.

For more information about BillionToOne and its pioneering diagnostic technologies, visit billiontoone.com.

Forward-Looking Statements
This announcement includes forward-looking statements concerning BillionToOne’s prospects and future developments, which entail inherent risks and uncertainties. While management bases these statements on current expectations, actual outcomes may differ significantly due to various factors. Careful consideration in reading, understanding, and acting upon these forward-looking statements is recommended.